524 related articles for article (PubMed ID: 12606517)
1. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
2. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
3. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
5. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
7. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
8. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
9. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
10. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.
Léger R; Thibaudeau K; Robitaille M; Quraishi O; van Wyk P; Bousquet-Gagnon N; Carette J; Castaigne JP; Bridon DP
Bioorg Med Chem Lett; 2004 Sep; 14(17):4395-8. PubMed ID: 15357960
[TBL] [Abstract][Full Text] [Related]
11. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
[TBL] [Abstract][Full Text] [Related]
12. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
13. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
14. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
Burcelin R; Dolci W; Thorens B
Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
[TBL] [Abstract][Full Text] [Related]
16. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
Islam MS; Rahman SA; Mirzaei Z; Islam KB
Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
[TBL] [Abstract][Full Text] [Related]
17. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
18. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
Lynch AM; Pathak N; Pathak V; O'Harte FP; Flatt PR; Irwin N; Gault VA
Diabetologia; 2014 Sep; 57(9):1927-36. PubMed ID: 24962667
[TBL] [Abstract][Full Text] [Related]
19. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.
Chen J; Bai G; Yang Y; Geng P; Cao Y; Zhu Y
Peptides; 2007 Apr; 28(4):928-34. PubMed ID: 17267075
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
